UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: November 22, 2013
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	000-54402	91-1835664
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification Number)

555 Heritage Drive, Jupiter, Florida	33458
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

BioRestorative Therapies, Inc. (the "Company") has prepared presentation materials (the "Presentation Materials") that management intends to use from time to time on and after November 22, 2013 in presentations about the Company's business. The Company intends to use the Presentation Materials, possibly with modification, at the 11th Annual Meeting of the International Federation for Adipose Therapeutics and Science on November 22, 2013 and may use the Presentation Materials in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business.

The information contained in the Presentation Materials is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The presentation materials will also be posted in the Investor Relations section of the Company's website, www.biorestorative.com for 90 days.

The information referenced under Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report on Form 8-K is being "furnished" under "Item 7.01. Regulation FD Disclosure" and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibit 99.1 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement, report or other document filed by the Company pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation Materials.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: November 22, 2013

By: /s/ Mark Weinreb
Mark Weinreb
Chief Executive Officer

Brown Adipose Derived Stem Cells

Francisco Silva

VP of Research and Development

BioRestorative Therapies, Inc.

OTCBB: BRTX

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the "Company") to develop its adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: (1) the Company's limited operating history, lack of revenues, substantial losses since inception, and substantial working capital deficiency and stockholders' deficiency, (2) the Company's ability to obtain sufficient financing to satisfy its debt obligations and funds its operations, (3) the ability of the Company to obtain reimbursement for its therapies from private and governmental insurers, (4) the Company's ability to build management, human resources and infrastructure necessary to support the growth of its business, (5) competitive factors beyond the Company's control,(6) scientific and medical developments beyond the Company's control, (7) the Company's ability to comply with applicable federal, state, local, and international governmental requirements, (8) the Company's ability to protect its proprietary rights both within and outside the United States, and (9) other factors discussed in the Company's periodic documents filed with the Securities and Exchange Commission (which are available for review at www.sec.gov). Given these uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

biorestorative therapies

Brown Adipose Stem Cells



Fig. 2. (A) PET-CT scan of 18F-FDG Uptake **(B)** H/E stain of Mediastinal adipose tissue biopsy. **(C)** UCP-1 immunohistochemistry of mediastinal adipose tissue biopsy.

Adipose Tissue in Humans



Fig. 1. (A) Mediastinal adipose tissue biopsy from a newborn. **(B)** Mediastinal adipose tissue biopsy from a 56 year old. **(C)** Mediastinal adipose tissue biopsy from an 80 year old. **(D-F)** H/E sections of biopsied tissue

Brown Adipose Stem Cells



% Cell Surface Marker Exprssion	Brown ADSC	White ADSC
CD90	99	99
CD166	100	99
STRO-1	3	1
CD44	100	100
CD45	<1	<1
CD133	<1	<1
CD34	3	2
LIN	1	11
TMEM-26	77	24
SSEA-4	94	9
CD106	4	1
CD73	100	100
CD117	<1	<1
CD105	97	68
HLA-DR,DP,DQ	<1	<1
HLA-A,B,C	99	87
CD86	<1	2
CD137	72	3

Fig. 3. (A) Gene expression profile of brown adipose derived stem cells compared to white adipose derived stem cells. **(B)** Cell surface profile of brown adipose derived stem cells.

biorestorative therapies

Brown Adipose Stem Cells



Fig. 4. Gene expression profile of brown adipose derived stem cells differentiated into brown adipocytes. B-134-adipo A-C represent BADSC cells differentiated into brown adipocytes. B-134-1-3 represent undifferentiated brown adipose derived stem cells.

biorestorative therapies

Brown Adipose Stem Cells



Fig. 5. (A) Western blot 21 days post FNDC5 induction. Lane 1 brown adipose derived stem cells directionally differentiated into brown adipocytes. Lane 2 undifferentiated brown adipose derived stem cells. **(B)** Transmission electron microscopy of 21 day brown adipocyte differentiation induced with FNDC5 demonstrate intracytoplasmic lipid vacuoles. **(C)** Alcian blue staining of brown adipose derived stem cells directionally differentiated into chondrocytes. **(D)** Fatty acid binding protein 4 (FABP4) immunocytochemistry of brown adipose derived stem cells induced to undergo white adipogenesis. **(E)** Alizarian red staining of brown adipose derived stem cells induced to undergo osteogenesis. **(F)** Undifferentiated BADSCs.

Brown Adipose Stem Cells

ORIGINAL ARTICLE

Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant

Subhadra C. Gunawardana and David W. Piston

Brown adipose tissue regulates glucose homeostasis and insulin sensitivity

Kristin I. Stanford, Roeland J.W. Middelbeek, Kristy L. Townsend, Ding An, Eva B. Nygaard, Kristen M. Hitchcox, Kathleen R. Markan, Kazuhiro Nakano, Michael F. Hirshman, Yu-Hua Tseng, and Laurie J. Goodyear

Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA

biorestorative therapies

Brown Adipose Stem Cells



Fig. 6. (A) SEM of brown adipose derived stem cells cultured on porous extracellular matrix scaffolds. **(B)** SEM of directionally differentiated brown adipocytes on scaffolds. **(C)** Transcriptional profile of brown adipose derived stem cells differentiated into brown and white adipocytes. **(D)** Fatty acid uptake of brown fat differentiated brown adipose derived stem cells at 7, 14 and 21 days post differentiation. **(E)** Functional mitochondrial respiration assay of brown adipose derived stem cells differentiated into brown adipocytes at 7, 14 and 21 days post differentiation.

Brown Adipose Stem Cells

Brown ADSC Scaffold



Brown ADSC Scaffold

Fig. 8. (A) SEM of brown adipose derived stem cells cultured and differentiated into brown adipocytes on porous extracellular matrix scaffolds. **(B)** Higher magnification of brown adipose derived stem cells cultured and differentiated into brown adipocytes on porous extracellular matrix scaffolds.

biorestorative therapies

Immortalized BADSC





Brown Adipose Stem Cells

STEM CELLS®

MANUSCRIPT SECTION: TISSUE-SPECIFIC STEM CELLS

Metabolically Active Human Brown Adipose Tissue Derived Stem Cells

Francisco J Silva*[1], Dolly J Holt*[1], Vanessa Vargas[1], James Yockman[1], Sihem Boudina[2], Donald Atkinson[1], David W Grainger[3], Monica P Revelo[4], Warren Sherman[5], David A Bull[1], Amit N Patel[1*]

[1]Department of Surgery, Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah 84112, USA.; [2]Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Utah 84112, USA.; [3]Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112, USA.; [4]Department of Pathology, University of Utah, Salt Lake City, Utah 84112, USA.; [5]Division of Cardiology, Columbia University Medical Center, New York, NY 10032, USA.

Key Words. Brown adipose tissue • stem cells • scaffolds • obesity • diabetes • adipose

biorestorative therapies